Medication review for drug interactions in chronic myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how your current leukemia medicines and herbal or plant-based products may interact, and how that could affect outcomes in chronic myeloid leukemia. It may help doctors better understand which drug combinations are safest and most effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic myeloid leukemia (CML).
- You currently take one of these targeted tablets: imatinib, nilotinib, dasatinib, or bosutinib.
- Your most recent lab test shows a molecular response below 4.5 log (your study team will check this).
- You can read and write in French (or at least complete study materials in French).
- You are not taking ponatinib.
- You are able to understand and participate in study procedures (no legal or medical/psychological limits that prevent participation).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a type of leukemia treatment called tyrosine kinase inhibitors affects blood sugar and cholesterol levels in people with chronic myeloid leukemia. It may help doctors understand and manage these side effects better.
This trial tests a new pill that may help people with chronic myeloid leukemia (CML) when other treatments have stopped working or caused side effects. It might offer another option for controlling the disease.
This study compares two different medicines for people with chronic myeloid leukemia (CML) whose current treatment with imatinib (Gleevec) has not worked well enough. It tests whether switching to dasatinib (Sprycel) or increasing the dose of imatinib to 600 mg helps get the disease under better control.
This trial tests whether having a specially trained nurse manage your care can improve outcomes for people with chronic myeloid leukemia (CML) who take oral medication. It may be a good fit if you are starting or changing oral therapy.
This study looks at how your 'biological age' (how old your body seems) affects how well you do on targeted therapy for chronic myeloid leukemia. It aims to personalize your care by combining age and frailty information.
This study reviews existing medical records of people with chronic myelogenous leukemia (CML) who were treated with specific FDA-approved targeted tablets (tyrosine kinase inhibitors) at MD Anderson but not on an MD Anderson clinical trial. It may help the hospital understand how these medicines are used in real-world care.
Hear when a new Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.